By Ben Butkus

University of Antwerp spinout Multiplicom last week received its first significant investment, a €2 million ($2.9 million) financing that will enable the company to pursue a CE Mark for in vitro diagnostic use of its multiplexed PCR assays for clinical breast cancer and cystic fibrosis sequencing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.